March 28, 2024—Labcorp and Opko Health announced they have entered into an agreement for Labcorp to acquire select assets of BioReference Health, a wholly owned subsidiary of Opko, for $237.5 million.
Read More »Labcorp gets exclusive license for Proteomedix prostate cancer test
June 2023—Proteomedix (Schlieren, Switzerland) announced an exclusive license agreement in which Labcorp will develop and commercialize its Proclarix prostate specific antigen test in the United States. Proclarix is performed using the same blood sample as a PSA test and is designed to help determine the risk of clinically significant prostate cancer for men who have an elevated total PSA and a digital rectal examination finding that indicates elevated prostate volume but who are not suspected of having cancer.
Read More »Enzo Biochem to sell clinical lab to Labcorp
March 20, 2023—Enzo Biochem announced it has entered into an agreement in which Labcorp will acquire the assets of its clinical laboratory division, Enzo Clinical Labs.
Read More »Labcorp, OmniSeq launch NGS genomic profiling device
July 2021—Labcorp and OmniSeq announced the launch of OmniSeq Insight, a pan-cancer, solid tumor test that combines genomic and immune profiling, including tumor mutational burden, microsatellite instability, and immune gene expression, and integrates next-generation sequencing technology.
Read More »Labcorp, OmniSeq launch Insight NGS genomic profiling testÂ
June 10, 2021—Labcorp and OmniSeq announced the launch of OmniSeq Insight, a next-generation–sequencing, pan-cancer, solid tumor test that combines genomic and immune profiling, including tumor mutational burden, microsatellite instability, and immune gene expression.
Read More »FDA authorizes direct-to-consumer COVID-19 test kit
January 2021—The FDA authorized the first COVID-19 direct-to-consumer test system—LabCorp’s Pixel COVID-19 Test Home Collection Kit, for use by any person 18 years and older without a prescription.
Read More »FDA authorizes direct-to-consumer COVID-19 test system
Dec. 10, 2020—The FDA authorized the first COVID-19 direct-to-consumer test system—LabCorp’s Pixel COVID-19 Test Home Collection Kit, for use by any person 18 years and older without a prescription.
Read More »Sysmex, LabCorp extend agreement
December 2019—Sysmex America and LabCorp announced an extension of their hematology automation agreement, to provide LabCorp Diagnostics’ primary reference laboratories with Sysmex America’s latest, upgraded XN-Series technology; the XN-9100 is a scalable, modular automation system that incorporates sample sorting robotics from Yaskawa Motoman.
Read More »South Bend Medical Foundation sells diagnostic lab to LabCorp
Aug. 2, 2019—South Bend Medical Foundation announced it will sell its diagnostic clinical laboratory testing assets to LabCorp. SBMF will reinvest the proceeds from the sale into the organization to further enhance and modernize facilities and procedures, ensure the ability to fund retiree pensions, and focus on its core business of pathology and blood banking services.
Read More »Walgreens, LabCorp to open 600 patient service centers
Oct. 12, 2018—Walgreens and LabCorp will open at least 600 LabCorp patient service centers at Walgreens stores across the United States over the next four years.
Read More »Put It on the Board, 8/16
August 2016—LabCorp will acquire Sequenom; New York ends state PT services; St. Jude lands CAP ISO 15189 accreditation; Epigenomics’ DNA test included in CRC guideline; OSU to deploy Inspirata digital pathology solution; Mindray’s clinical chemistry analyzer cleared; Successful Keytruda trial stopped early; Top court clarifies autopsy’s place in Texas law; EUA for Siemens Zika assay
Read More »LabCorp biorepository receives CAP accreditation, 2/13:113
LabCorp recently announced that its biorepository has been accredited by the College of American Pathologists.
Read More »